Trapping and dissociation of propafenone derivatives in HERG channels

British Journal of Pharmacology

Volumn 162, Issue 7, 2011, Pages 1542-1552

  Windisch, A ^a   Timin, E N ^a   Schwarz, T ^a   Stork Riedler, D ^a   Erker, T ^a   Ecker, G F ^a   Hering, S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

arrhythmia; drug trapping; HERG; K channels; propafenone; QT syndrome; voltage clamp; Xenopus oocyte

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; GPV 005; GPV 009; GPV 019; GPV 031; GPV 062; GPV 180; GPV 574; GPV 576; GPV 929; POTASSIUM CHANNEL HERG; PROPAFENONE; SCT AS03; SCT ASO3; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISSOCIATION; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; IC 50; MICROELECTRODE; MOLECULAR WEIGHT; NONHUMAN; PHARMACOPHORE; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT INTERVAL; REPOLARIZATION; STEADY STATE; VOLTAGE CLAMP; XENOPUS;

ACTION POTENTIALS; ANIMALS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; KINETICS; MOLECULAR WEIGHT; PATCH-CLAMP TECHNIQUES; POTASSIUM; PROPAFENONE; PROTEIN CONFORMATION; XENOPUS LAEVIS;

EID: 79952370925     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01159.x     Document Type: Article

References (33)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Arias C, Gonzalez T, Moreno I, Caballero R, Delpon E, Tamargo J, et al. (2003). Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels. Cardiovasc Res 57: 660-669. (Pubitemid 36254860)
3. Baburin I, Beyl S, Hering S, (2006). Automated fast perfusion of Xenopus oocytes for drug screening. Pflügers Arch 453: 117-123. (Pubitemid 44454892)
4. Campbell TJ, (1983). Importance of physico-chemical properties in determining the kinetics of the effects of Class I antiarrhythmic drugs on maximum rate of depolarization in guinea-pig ventricle. Br J Pharmacol 80: 33-40. (Pubitemid 13000876)
5. Carmeliet E, (1992). Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 262: 809-817.
6. Chiba P, Ecker G, Schmid D, Drach J, Tell B, Goldenberg S, et al. (1996). Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Mol Pharmacol 49: 1122-1130.
7. Courtney KR, (1980). Structure-activity relations for frequency-dependent sodium channel block in nerve by local anesthetics. J Pharmacol Exp Ther 213: 114-119. (Pubitemid 10099034)
8. Decher N, Kumar P, Gonzalez T, Pirard B, Sanguinetti MC, (2006). Binding site of a novel Kv1.5 blocker: a 'foot in the door' against atrial fibrillation. Mol Pharmacol 70: 1204-1211. (Pubitemid 44435971)
9. Fermini B, Fossa AA, (2003). The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2: 439-447. (Pubitemid 37361725)
10. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, et al. (2000). The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47: 219-233. (Pubitemid 30625285)
11. Hille B, (1977). Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol 69: 497-515. (Pubitemid 8086978)
12. Hille B, (2001). Ion Channels of Excitable Membranes. Sinauer Associates Inc.: Sunderland, MA.
13. Kamiya K, Mitcheson JS, Yasui K, Kodama I, Sanguinetti MC, (2001). Open channel block of HERG K(+) channels by vesnarinone. Mol Pharmacol 60: 244-253. (Pubitemid 32678288)
14. Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC, (2006). Molecular determinants of HERG channel block. Mol Pharmacol 69: 1709-1716.
15. Keating MT, Sanguinetti MC, (2001). Molecular and cellular mechanisms of cardiac arrhythmias. Cell 104: 569-580. (Pubitemid 32201951)
16. Kikuchi K, Nagatomo T, Abe H, Kawakami K, Duff HJ, Makielski JC, et al. (2005). Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol 144: 840-848. (Pubitemid 40516123)
17. Klein C, Kaiser D, Kopp S, Chiba P, Ecker GF, (2002). Similarity based SAR (SIBAR) as tool for early ADME profiling. J Comput Aided Mol Des 16: 785-793. (Pubitemid 36701514)
18. Mitcheson JS, (2008). hERG potassium channels and the structural basis of drug-induced arrhythmias. Chem Res Toxicol 21: 1005-1010.
19. Mitcheson JS, Perry MD, (2003). Molecular determinants of high-affinity drug binding to HERG channels. Curr Opin Drug Discov Devel 6: 667-674. (Pubitemid 37287935)
20. Mitcheson JS, Chen J, Sanguinetti MC, (2000). Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol 115: 229-240.
21. Perry M, de Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC, et al. (2004). Structural determinants of HERG channel block by clofilium and ibutilide. Mol Pharmacol 66: 240-249. (Pubitemid 38989480)
22. Sanchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, Sanguinetti MC, (2002). Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. J Biol Chem 277: 23587-23595. (Pubitemid 34952195)
23. Sanguinetti MC, Tristani-Firouzi M, (2006). hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469.
24. Sanguinetti MC, Xu QP, (1999). Mutations of the S4-S5 linker alter activation properties of HERG potassium channels expressed in Xenopus oocytes. J Physiol 514 (Pt 3): 667-675. (Pubitemid 29060313)
25. Sanguinetti MC, Jiang C, Curran ME, Keating MT, (1995). A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81: 299-307.
26. Stork D, Timin EN, Berjukow S, Huber C, Hohaus A, Auer M, et al. (2007). State dependent dissociation of HERG channel inhibitors. Br J Pharmacol 151: 1368-1376. (Pubitemid 47255915)
27. Thai KM, Windisch A, Stork D, Weinzinger A, Schiesaro A, Guy RH, et al. (2010). The hERG potassium channel and drug trapping: insight from docking studies with propafenone derivatives. ChemMedChem 5: 436-442.
28. Tseng GN, (2001). I(Kr): the hERG channel. J Mol Cell Cardiol 33: 835-849.
29. Viskin S, (1999). Long QT syndromes and torsade de pointes. Lancet 354: 1625-1633. (Pubitemid 29515963)
30. Witchel HJ, Dempsey CE, Sessions RB, Perry M, Milnes JT, Hancox JC, et al. (2004). The low-potency, voltage-dependent HERG blocker propafenone- molecular determinants and drug trapping. Mol Pharmacol 66: 1201-1212. (Pubitemid 39411060)
31. Yeh JZ, Armstrong CM, (1978). Immobilisation of gating charge by a substance that simulates inactivation. Nature 273: 387-389. (Pubitemid 8344184)
32. Yeh JZ, TenEick RE, (1987). Molecular and structural basis of resting and use-dependent block of sodium current defined using disopyramide analogues. Biophys J 51: 123-135. (Pubitemid 17229841)
33. Zou A, Curran ME, Keating MT, Sanguinetti MC, (1997). Single HERG delayed rectifier K+ channels expressed in Xenopus oocytes. Am J Physiol 272 (3 Pt 2): H1309-H1314.